Skip to main content
Navamedic logo

Navamedic — Investor Relations & Filings

Ticker · NAVA ISIN · NO0010205966 LEI · 529900LKVQOR2SRUJU71 OL Wholesale and retail trade
Open in API
Filings indexed 825 across all filing types
Latest filing 2021-04-30 Annual Report
Country NO Norway
Listing OL NAVA

About Navamedic

https://navamedic.com/

Navamedic is a pharmaceutical company that develops, produces, and commercializes a diverse portfolio of medicines and related health products. The company's offerings include specialty pharmaceuticals, branded generics, and consumer health items. Its product portfolio addresses various medical needs, with treatments for conditions such as obesity, Parkinson's disorder, and inborn errors of metabolism, in addition to antibiotics. Serving as a reliable supplier and distribution partner, Navamedic provides high-quality products to hospitals and pharmacies, with a strong presence in the Nordic region and the Netherlands. The company focuses on improving patient outcomes through innovations, including advancements in personalized treatment for Parkinson's care.

Recent filings

Filing Released Lang Actions
Navamedic ASA: Annual report 2020
Annual Report Classification · 100% confidence The document is explicitly titled 'Annual report 2020' and contains comprehensive sections including highlights, key figures, CEO comments, directors' report, consolidated financial statements, notes to the financial statements, and an auditor's report. It covers the full fiscal year 2020 and provides detailed financial performance and business analysis, which aligns perfectly with the definition of a 10-K (Annual Report). FY 2020
2021-04-30 Norwegian
Navamedic ASA: Annual report 2020
Report Publication Announcement Classification · 99% confidence The document is explicitly titled "Navamedic ASA: Annual report 2020". Although it contains highlights and mentions the report is attached, the content is substantial enough (discussing full-year revenue, EBITDA, margin improvement, acquisitions, and strategic investments for the entire year 2020) to be classified as the Annual Report itself, rather than just a brief announcement of publication. The 10-K code is the standard classification for official yearly reports covering full financial performance, which aligns with the content described as the 'Annual report 2020'. The document length (3565 chars) is significant for a mere announcement, further supporting classification as the report content.
2021-04-30 English
Navamedic ASA: Enters long term distribution agreement for PrecisionBiotics Zenflore® in the Nordics with Novozymes.
M&A Activity Classification · 99% confidence The document is a press release announcing a long-term exclusive distribution agreement between Navamedic ASA and Novozymes for a specific product (Zenflore®) in the Nordics. This type of announcement, detailing a significant business development, partnership, or contract, does not fit neatly into the specific financial reporting categories (like 10-K, ER, IR) or corporate governance filings (like DEF 14A, DVA). It is a general business update. Since it is not a formal regulatory filing like a 10-K or a specific financial event like a dividend announcement or earnings release, the most appropriate fallback category is 'Regulatory Filings' (RNS), which serves as a general category for miscellaneous official announcements that do not fit elsewhere, especially those released via stock exchange news services.
2021-04-08 English
Transaction by primary insider's close associate
Director's Dealing Classification · 99% confidence The document is explicitly titled "Notification of transactions by Primary Insiders and Close Associates." It details a transaction (pedging of shares) involving a Primary Insider's close associate (Ingerø Reiten Investment Company AS) and a Board Member (Narve Reiten) of Navamedic ASA. This type of filing, reporting personal share transactions by company directors and executives (insider trades), directly corresponds to the definition of Director's Dealing.
2021-03-26 English
Transaction by primary insider's close associate
Director's Dealing Classification · 98% confidence The document explicitly states 'Transaction by primary insider's close associate' and details a pledge of shares (3,563,042 Navamedic ASA shares) made by an entity related to an insider in connection with a loan facility. This directly relates to personal share transactions by company directors or executives and their associates, which corresponds to the Director's Dealing category.
2021-03-26 English
Navamedic ASA: Resultater for fjerde kvartal 2020
Earnings Release Classification · 99% confidence The document text explicitly details 'Q4 2020 Fourth quarter results 2020' for Navamedic ASA, presenting key financial metrics (Revenue, Gross Margin, EBITDA) for the quarter and year-to-date, along with comparative figures from Q4 2019. It includes detailed tables for the Profit and Loss statement and Balance Sheet summaries, and discusses outlook. This content structure is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, often presented in a slide deck format like this one, rather than the comprehensive, formally filed Annual Report (10-K) or the detailed Management Discussion and Analysis (MDA). Since it focuses on the immediate results announcement, ER is the most appropriate classification. Q4 2020
2021-02-18 Norwegian

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.